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Objective: Until the present moment, the lack of efﬁcient therapeutic options available for
hyperhidrosis treatment in obese patients has left this population without prospect of clini-
cal  or quality of life (QOL) improvements. Outcomes of oxybutynin treatment for overweight
and obese patients with hyperhidrosis are unknown. This study aims to investigate the
results related to clinical and QOL improvements in this speciﬁc population, submitted to a
12-week protocol treatment with oxybutynin.
Methods: 559 patients with palmar and axillary hyperhidrosis, routinely followed in this
service, were divided into the groups, according to their body mass index (BMI) (< 25 kg/m2;
25  < BMI < 30 kg/m2, > 30 kg/m2). Improvements in QOL and in the level of hyperhidrosis
were analyzed after 12 weeks of protocol treatment with oxybutynin. These parameters were
investigated using a scoring system based on a scientiﬁcally validated clinical questionnaire,
applied before and after treatment.
Results: 67.8% of the overweight sample group and 63% of the obese patients presented
“partial” or “great” improvement in the level of hyperhidrosis. Over 65% of patients demon-
strated improvement in QOL (“much better” or “slightly better”) for all three groups, with
no statistical difference between them. The only adverse event associated with oxybutynin
was dry mouth, observed in 63.0% of the patients.
Conclusion: Overweight and obese patients with palmar or axillary hyperhidrosis present
signiﬁcant improvement in QOL after treatment with oxybutynin, and the results are com-
parable to those of normal weight individuals.
© 2013 Elsevier Editora Ltda.    
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Tratamento
Simpatectomia
Qualidade de vida
Obesidade
qualidade de vida. Resultados do tratamento com oxibutinina especiﬁcamente em pacientes
com sobrepeso ou obesidade são desconhecidos até o presente momento. Este estudo tem
como  objetivo investigar os resultados relacionados à melhora clínica e qualidade de vida
dessa populac¸ão, após um protocolo de tratamento de 12 semanas com oxibutinina.
Métodos: 559 pacientes com hiperidrose palmar e axilar, foram divididos em três grupos, de
acordo com seu índice de massa corporal (IMC) (< 25 kg/m2; 25 < IMC < 30 kg/m2, > 30 kg/m2).
Dados sobre evoluc¸ão na qualidade de vida e nível de hiperidrose foram avaliados com
base  em um questionário validado cientiﬁcamente, aplicado antes e após o tratamento
com oxibutinina.
Resultados: 67.8% dos pacientes com sobrepeso e 63% dos obesos apresentaram melhora
clínica “grande” ou “parcial” no nível da hiperidrose. Mais de 65% dos pacientes relataram
melhora na qualidade de vida (“muito melhor” ou “um pouco melhor”) para os três gru-
pos,  sem diferenc¸a estatística entre eles. O único efeito colateral observado foi boca seca,
presente em 63.0% da amostra.
Conclusão: Pacientes com sobrepeso e obesidade portadores de hiperidrose palmar ou axilar
apresentaram melhora signiﬁcativa na qualidade de vida após o tratamento com oxibutin-
ina,  sendo os resultados comparáveis aos de indivíduos com peso normal.
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Introduction
Hyperhidrosis is the production of excessive sweat beyond
what is required for the body’s thermoregulatory needs.1 Pal-
mar  (PH), plantar (PlH), and axillary hyperhidrosis (AH) are the
most frequent presentations in both genders and across all age
groups. Hyperhidrosis affects approximately 3% of the general
population, and actively interferes with patients’ quality of life
(QOL), causing issues in social, professional, and emotional
spheres.2 The psychological stress caused by excessive sweat-
ing is the main drive for patients to seek medical assistance,
who  are usually willing to undergo any possible treatment
option that will improve their QOL. Until the present moment,
the lack of efﬁcient therapeutic options available for hyper-
hidrosis treatment in obese patients has left this population
without prospect of improvements in QOL.
Overweight and obesity, deﬁned as body mass index (BMI)
greater than 25 kg/m2 and 30 kg/m2, respectively, are the main
conditions associated with more  severe sweating, possibly
as a result of reduced heat loss due to thicker layers of fat
in subcutaneous tissues. These patients have greater difﬁ-
culty in maintaining normal body temperature levels, and
therefore produce excessive perspiration as a compensatory
mechanism.3
Video-assisted thoracic sympathectomy (VATS) is currently
considered the optimal technique for treatment of primary
hyperhidrosis. It is a safe, effective, and minimally inva-
sive method;4–7 however, it presents limited applicability
in obese patients. Increased surgical risk, technical limita-
tions, and more  severe levels of compensatory hyperhidrosis
explain why surgical indications are greatly restricted in these
individuals.8
Oxybutynin is an anticholinergic medication widely used
in urology for treatment of bladder urge incontinence. Sweat
glands are stimulated by acetylcholine; thus, the anticholin-
ergic effect of oxybutynin is responsible for its effectiveness
against excessive sweating.9 It is a safe medication, with
few absolute contraindications; the most important is closed-
angle glaucoma. Potential side effects include dry mouth,sevier Editora Ltda.    
constipation, headache, nausea, and urinary retention. Few
drug interactions have been reported, and when present, they
involve concomitant use of cytochrome P450 metabolism-
dependent medications.10,11
Recent studies have disclosed good results with the use of
oxybutynin for the treatment of hyperhidrosis.12–15 Nonethe-
less, a speciﬁc analysis of the effectiveness of this medication
in obese patients had not been conducted. This study aimed
to analyze QOL after treatment with oxybutynin in obese
patients with PH and AH, and to compare the results with
those of normal weight individuals.
Methods
This was a retrospective study, based on medical chart review
of 559 patients treated with oxybutynin from January 2007 to
December 2011. The study was approved by the ethics com-
mittee of the institution.
The patients involved were divided into three groups
according to their BMI. The ﬁrst group was composed of 411
(73.5%) normal weight patients (BMI < 25 kg/m2), the sec-
ond consisted of 121 (21.6%) overweight patients (25< BMI
< 30 kg/m2), and the third, of 27 (4.9%) obese individuals (BMI
< 30 kg/m2).
Age, gender distribution, and location of hyperhidrosis
according to BMI  are shown in Table 1. The lowest average
age was observed in the normal weight group. PH and female
gender were predominant in all weight categories.
The same medical treatment protocol was applied to all
patients. During the ﬁrst week, 2.5 mg  of oxybutynin were
administered once a day in the evening. From the eighth to
the 42nd day, the patients received 2.5 mg  of the medication
twice a day; from the 43rd day to the end of the 12th week, 5 mg
were administered twice a day. Experience has shown that a
staged administration reduces the impact of anticholinergic
Este é um artigo Open Access sob a licença de CC BY-NC-NDside effects.
Patients were analyzed in three different moments dur-
ing the study. The ﬁrst evaluation was performed before the
start of medication; the second, after six weeks of treatment;
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Table 1 – Age, site of hyperhidrosis, and gender distribution according to BMI.
BMI p
Variable < 25 25 < BMI < 30 > 30
n (%) n (%) n (%)
Age
n 411  121 27
Range (min-max) 9-58 15-61 17-51 < 0.01a
Mean ± SD 24.18 (±9.35) 30.0 (± 8.95) 30.8 (± 9.33)
Median 24 29 29
Site of hyperhidrosis
Axilar 185 (45.0) 56 (46.3) 17 (62.9) 0.059b
Palmar 266 (55.0) 65 (53.7) 10 (37.1)
Gender
Female 310 (75.4) 64 (52.9) 16 (59.2) < 0.0001b
Male 101 (24.6) 57 (47.1) 11 (40.8)
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tBMI, body mass index.
a Student’s t-test;
b Chi-squared test.
nd the last evaluation, after the completion of 12 weeks of
reatment. These evaluations were used to follow-up patients’
linical and QOL improvement. Clinical improvement was
lassiﬁed using a scale ranging from 0 to 10, where 0 rep-
esented no improvement, and 10 represented absence of
yperhidrosis. Clinical outcomes were ranked according to the
ollowing categories: null (from 0 to 4), partial (5 to 7), or great
8 to 10).
QOL analysis was based on a validated clinical protocol
uestionnaire, applied at each visit.16,17 The questionnaire
as completed according to the patient’s perception of hyper-
idrosis improvement, without examiners’ interference. The
uthors believe that self-evaluation is a reliable method for
atient QOL analysis.
QOL before treatment was classiﬁed into ﬁve different sat-
sfaction categories, calculated as the added total score from
he protocol (ranging from 20 to 100). According to the sco-
ing system, a greater score reﬂects a more  signiﬁcant impact
nd represents poorer QOL. When the total score was equal
o or greater than 84, QOL was considered “very poor”. When
he total score ranged from 68 to 83, QOL was considered
poor”. Scores that ranged from 52 to 67 were considered
good”. Scores from 36 to 51 indicated “very good” results, and
cores from 20 to 35 were considered “excellent.
Similarly, improvement of QOL after treatment was also
lassiﬁed into ﬁve different levels. When the total was equal
o or greater than 84, the QOL was considered to be “worse”.
hen the scores ranged from 68 to 83, QOL was considered
o be “slightly worse”. Scores from 46 to 58 were considered
unaltered”. Scores from 33 to 45 indicated a “slight improve-
ent”, and scores from 17 to 32 were considered “much
etter”.
The following parameters were studied in both groups:
rogress of PH and AH, evaluation of QOL before treatment,
nd improvement in QOL after treatment.tatystical  analysis
he chi-squared test was performed to verify the associa-
ion between categorical variables in contingency tables, andStudent’s t-test was used to compare age and study group. The
signiﬁcance level considered for all statistical tests was 0.05.
Results
All patients enrolled in the present study classiﬁed their QOL
before treatment as “poor” or “very poor”, as demonstrated in
Table 2. According to the present results, obese patients con-
sidered themselves less affected by hyperhidrosis than normal
or overweight individuals.
Approximately 69% of the normal BMI  group classiﬁed their
QOL before treatment as “very poor”, whereas over 80% of
obese individuals ranked their QOL as simply “poor”. The
questionnaire was re-applied after the proposed period of
treatment; over 65% of patients demonstrated improvement
in QOL (“much better” or “slightly better”) for all three groups,
with no statistical difference between them (Table 2).
Table 3 shows clinical improvement in hyperhidrosis,
according to a subjective evaluation based on the patient’s per-
ception of his/her own symptoms. Over 60% of the patients in
all groups presented partial or great improvement in the level
of sweating.
The only adverse event associated with oxybutynin was dry
mouth, observed in 255 cases (63.0%); however, none required
discontinuation of treatment, since in most cases the symp-
tom was classiﬁed as “light” and therefore tolerable.
Discussion
Obesity is a condition with increasing incidence and preva-
lence in many  parts of the world, and results from an
interaction of the environment, associated with genetic
predisposition and overall human behavior.15 Overweight
patients present increased risk of several diseases including
hypertension, osteoarthritis, diabetes, certain cancers, as well
as psychological disorders.18,19 Concomitant hyperhidrosis
may aggravate a negative emotional state, resulting in further
deterioration of overall health conditions. This reinforces the
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Table 2 – Quality of life before and after treatment according to BMI.
QOL before treatment Score BMI < 25 n (%) 25 < BMI < 30 n (%) BMI > 30 n (%) pa
Very poor 84-100 283 (68.8) 41 (33.9) 5 (18.5) < 0.001
Poor 68-83 128 (31.2) 80 (66.1) 22 (81.5)
Good 52-67 - - -
Very good 36-51 - - -
Excellent 20-35 - - -
Total 411 121 27
QOL after treatment Score BMI < 25 n (%) 25 < BMI < 30 n (%) BMI > 30 n (%) pb
Much better 17-32 140 (34.1) 37 (30.5) 5 (18.5)
Slightly better 33-45 145 (35.3) 45 (37.2) 13 (48.1)
Unaltered 46-58 126 (30.6) 39 (32.3) 9 (33.4) 0.917
Slightly worse 68-83 - - -
Worse 84-100 - - -
Total 411 121 27
lightla Chi-squared test;
b Chi-squared test comparing “unaltered” with “much better” and “s
signiﬁcant need for a deﬁnitive treatment of hyperhidrosis in
this speciﬁc population.
BMI  is an estimation of body fat based on the ratio of a
patient’s height to weight. Despite its limitations, it is one of
the most commonly used anthropometric measures to assess
total body adiposity, due to its simplicity, acceptable accuracy,
and inexpensiveness.20 BMI  measurements are extensively
used in epidemiological studies, and are recommended as a
screening tool in the initial clinical assessment of obesity.12
The Centers for Disease Control and Prevention deﬁned
BMI  classiﬁcation as follows: 1) underweight: BMI < 18.5 kg/m2;
2) normal or acceptable weight: BMI  18.5–24.9 kg/m2; 3) over-
weight: BMI  25–29.9 kg/m2; 4) obese: BMI  > 30 kg/m2.21 For the
purpose of the present study, the relevant BMI cutoff is 25,
since surgical procedures are limited in patients with BMI
above this level.8
Unspeciﬁc questionnaires for QOL assessment do not allow
for a precise analysis of patients with hyperhidrosis, since rel-
evant information for this disorder is not ordinarily addressed.
The QOL questionnaire used in this study has been validated
and used in several published documents.13,14 Its questions
focus on inﬂuence of hyperhidrosis in different daily life situ-
ations, involving social, emotional, and professional activities.
The higher predominance of hyperhidrosis observed in the
female gender is consistent with previous studies, and can be
explained by the greater concern that this condition imposes
to women, leading them to seek medical assistance more
often.22
Table 3 – Improvement in hyperhidrosis after treatment.
Treatment result Score BMI < 25
n (%)
No improvement 0-4 115 (28.0) 
Partial improvement 5-7 141 (34.3) 
Great improvement 8-10 155 (37.7) 
Total 411 
∗ Chi-squared test comparing “no improvement” with “partial improvemey better”.
The group with BMI < 25 km/m2 showed a predominance
of “very poor” QOL classiﬁcation, higher than that observed in
the other two groups. Therefore, a direct relationship between
level of obesity and QOL before treatment was not clearly
established in these study patients.
Improvements in hyperhidrosis after treatment were sim-
ilar in all three groups, suggesting that overweight and obese
patients beneﬁt similarly to normal weight patients. This
may be explained by the fact that QOL in patients with
hyperhidrosis depends not only on the intensity of sweat-
ing, but also on how well the patient adapts to his/her
situation.5 Normal weight individuals suffering with hyper-
hidrosis may perceive their condition as greater in severity.
Excess weight patients may endure other more important
worries, and therefore may give less importance to hyper-
hidrosis.
Reports on safety and adverse events regarding oxybutynin
are based on the knowledge for treatment of urological blad-
der conditions.23 Anticholinergic side effects are the most
frequent, and can occur in over 70% of patients using over
15 mg/day. The dose administered to the present patients was
rather low (10 mg/day) in comparison to what is commonly
used for urological purposes (15 mg/day), and this may explain
the low incidence of side effects observed in this study. Dry
mouth is usually benign and decreases with time of use of
medication. In this study there were no reported cases of
treatment interruption or discontinuation due to side effects.
However, more  severe and persistent side-effects can occur,
25  < BMI < 30
n (%)
BMI  > 30
n (%)
p*
39 (32.2) 10 (37.0) 0.444
35 (28.9) 8 (29.6)
47 (38.9) 9 (33.4)
121 27
nt” and “great improvement”.
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specially with higher doses, and may be a limiting factor for
ong-term use of this medication.24
onclusion
verweight and obese patients with PH or AH reported a sig-
iﬁcant reduction in sweating and improvement in QOL after
reatment with oxybutynin; the results are comparable to nor-
al  weight individuals. The use of oxybutynin in low doses
hould be considered as a simple and efﬁcient therapeutic
lternative to improve the QOL of these patients. Further stud-
es are required to analyze the long-term use and safety of this
edication.
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